ÂÜÀòÂÒÂ×

Alexis Vandier currently serves as Global Asset Lead, Oncology at Servier since May 2023. Additionally, Alexis holds advisory roles at Parean Biotechnologies, Extens e-santé, and BNP Paribas Développement since January 2021, providing insights in research, investment strategy, and eHealth. Previously, positions included Chief Executive Officer at OSE Immunotherapeutics (June 2022 - February 2023) and Vice President, Global Asset Lead, Oncology at Ipsen (2010 - 2022), overseeing R&D and business functions related to Cabometyx. Alexis has a robust educational background, with recent studies at Harvard Medical School and an Executive Module from London Business School, alongside degrees in Economics and Sciences from Université Lumière Lyon 2 and Centrale Lyon.